Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects With Idiopathic Pulmonary Fibrosis

NCT04533022 is registered in ClinicalTrials.gov with Vicore Pharma AB as lead sponsor.

NCT NCT04533022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04533022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects With Idiopathic Pulmonary Fibrosis
Lead sponsor
Vicore Pharma AB
Phase
Phase 2
Overall status
Completed
Start date
November 13, 2020
Completion date
March 30, 2024
Enrollment
52 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis